Available in English, French, Spanish, Russian, Chinese, Arabic and Portugues
Harm Reducation, Decriminalization and Zero Discrimination for People who use Drugs
Lancet Psychiatry 2016;3: 415–24
This document builds on the Background document prepared for the September 4-5, 2014 Consultation. It includes proposed elements to consider during the development of a framework to assist decision-making at global and national level.
The aim of the document is to assist Member States and releva...nt partners in their discussions to identify the best approaches to ensure the accelerated evaluation and use of available or near-term therapies and vaccines for the treatment and prevention of EVD. The document calls for a coordinated effort by the international community to remove unnecessary obstacles towards this goal.
more
Good practice examples from India
Amphetamine-type stimulants, new psychoactive substances
-4-
World Drug Report 2017
Accessed: 14.03.2019
World Drug Report 2017
-1-
Accessed: 14.03.2019
An update from the EU Early Warning System
WHO Western Pacific Regional Strategy to Reduce Alcohol-Related Harm
Position Statement
Diabetes Care2018;42(Suppl. 1):S1–S194.
New criteria for classifying and diagnosing hyperglycaemia first detected during pregnancy have been accepted by a group of experts convened by WHO. These new criteria are an update of recommendations published by WHO in 1999
EMCDDA Insights - 11
Accessed: 14.03.2019
Opiates, cocaine, cannabis
World Drug Report 2017
-3-
Accessed: 14.03.2019
Depression is a leading cause of non-fatal disease burden worldwide, with a lifetime prevalence of 9% among European adult men and 17% among European adult women.
The task at hand requires substantial investments in preventive mental health care, but the potential benefits can be equally rewarding.... After all, mental wellbeing is a key resource for learning, productivity, participation and inclusion. Investing in proactive care to promote, protect and sustain mental health in the population is therefore likely to offer good value for money.
more
Conducted November 2011 to February 2012: Summary Report
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle...d. Section 4 highlights key achievements and enabling factors for the response to artemisinin resistance, whilst Section 5 provides a more detailed discussion of major issues to be addressed.
more
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/MDR-TB cases eligible for treatment. Extensively drug-resistant TB (XDRTB) has also been reported from s...ix countries of the SEA Region. MDR-TB could potentially replace drug-susceptible TB, and constitutes a threat to global public health security. The South- East Asia Regional Response Framework for DR-TB 2017–2021 complements the Ending TB in the South-East Asia Region: Regional Strategic Plan 2016–2020” and outlines key strategies for reducing morbidity, mortality and transmission of DR-TB.
more
The report reflects on the trends, achievements and challenges in global health over the past decade during which Dr Margaret Chan has been Director-General of WHO. It discusses the role of WHO in dealing with such issues as the rise of noncommunicable diseases, leaps in life expectancy, and emergin...g threats like climate change and antimicrobial resistance.
more